Page 20 - CIBERES-2015-eng

Scientific Programmes
Chronic Obstructive
Pulmonary Disease (COPD)
COORDINATOR: DR . BORJA GARCÍA-COSÍO ACCOMPLISHMENTS IN 2015:
1. Activity of the disease and care in fragile pa- tients. We have generated the DELICATO cohort of patients with advanced COPD and performed a clinical audit of 1440 cases in 40 Spanish
ities and that the model of right-sided heart failure is associated with oxidative muscular stress.
The therapeutic trials were completed with guanylate cyclase stimulators in a model of
hospitals 530 of these patients are included in the BIOME- POC-CIBERES biomarkers cohort.
2. Markers of activity in COPD. Everything is ready to carry out the determinations on human and animal samples, after having obtained the bio- logical samples from different studies, cohorts of fragile COPD (BIOMCOPD), of early starting COPD (Early-COPD) and from the animal mod- els performed.
In the microbiological sphere we have defined the markers associated with COPD after com- pleting a systematic analysis of the respiratory microbiome existing in two cohorts of COPD in a stable situation and undergoing exacerbation and we have identified the interferences exist- ing between the bacterial pathogeny and the therapeutic response during infection. We have described the structure of the bacterial and vi- ral microbiomes present in the stable and exac- erbation situations, in the presence or absence of P. Aeruginosa and finally we have identified the phenotypes of NT Haemophilus influenzae and its relations with pathogenicity in COPD.
3. Potential markers of activity in animal models of fragile and early-starting COPD. We conclud- ed the experiments for characterising a murine model of early starting COPD by controlled ex- posure to tobacco smoke and at the present time the data collected on morphometry, im- age, function, transcriptomics and proteomics is being processed. As regards the fragile COPD model, we have developed severe pulmonary hypertension in the murine model of hypox- ia and SU5416. We have also shown that the models of acute hypoxia and/or hypercapnia in rats develop lesions and signs of regeneration of the respiratory muscles and of the extrem-
exposure to tobacco in guinea pigs, as well as LGF treatment in a previously established mu- rine model of emphysema.
We have prepared a protocol for function- alisation of nanoparticles for dual applica- tion, PET and magnetic resonance (Patent WO2014006254 A1), of potential application in the diagnosis and treatment of COPD.
4. Characterisation and determinants of activity in COPD. We completed the design of the Ear- ly-COPD cohort and the recruitment started in January 2015, with the participation of pneu- mologists and primary healthcare doctors. Un- til now 140 cases have been recruited. We have closed a cooperation agreement with the sci- entific committee of the PESA study to include new variables facilitating the study of the start of COPD. The PESA study is carried out by the CNIC on a cohort of over 3500 employees of the Banco Santander to study the evolution of factors of cardiovascular risk.
20 I Annual report 2015 I CIBERES